EMG
ALBO

Ellington Management Group’s Albireo Pharma Inc ALBO Stock Holding History

Ellington Management Group’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,500
Closed -$444K – 740
2018
Q2 		$444K Buy
+12,500
New +$405K 0.03% 193

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Ellington Management Group's ALBO Position: Q3 2018 in Review

Ellington Management Group sold out of Albireo Pharma Inc (ALBO) in Q3 2018, closing a stake of 12,500 shares — an estimated $444K sold.

Ellington Management Group first reported a position in ALBO in Q2 2018 and held it in 1 quarter. The position peaked at $444K in Q2 2018. 67 funds tracked by Wall St. Rank hold ALBO as of Q3 2018.

  • Ellington Management Group reported no remaining Albireo Pharma Inc position as of Q3 2018 after selling out during the quarter.
  • Ellington Management Group sold 12,500 Albireo Pharma Inc shares in Q3 2018, an estimated $444K.
  • Ellington Management Group first reported a position in Albireo Pharma Inc in Q2 2018 and held it in 1 quarter.
  • Ellington Management Group's Albireo Pharma Inc position peaked at $444K in Q2 2018.
  • 67 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2018.

Based on Ellington Management Group's 13F filing for Q3 2018, filed 14 Nov 2018.